Fast Five Quiz: Metastatic Non–Small Cell Lung Cancer

Winston W. Tan, MD, FACP


March 29, 2022

Patients with metastatic disease should undergo PD-L1 testing, and those who have PD-L1 are candidates for the combination therapy of nivolumab and ipilimumab. The presence of an oncogene and candidacy for immune checkpoint inhibitors with tumor histology and performance status and comorbidities should be factored into treatment considerations. First-line, single-agent pembrolizumab is indicated for metastatic NSCLC whose tumors express PD-L1 with no EGFR genomic aberrations.

Learn more about treatment protocols for metastatic NSCLC.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.